Healthcare Pharmaceuticals Ltd launches Eli Lilly’s New Meal-Time Insulin Humalog® 200 KwikPen®®

Publish: 9:49 PM, November 12, 2022 | Update: 9:49 PM, November 12, 2022

Healthcare Pharmaceuticals Ltd. (HPL) on Friday announced the launch of Eli Lilly’s Humalog® 200 (Insulin Lispro 200 Units/ml) KwikPen® in Bangladesh. Humalog® 200 is the concentrated, rapid acting analogue insulin designed to improve blood sugar control in adults with both Type 1 and Type 2 diabetic. Humalog® 200 is US-Food and drug Administration approved medicine and manufactured by Eli Lilly & Company.
Over the time, some diabetic patients may require dosage increase of their insulin for improved glycaemic control. Patients who are obese, have high insulin resistance and requires large daily dose of mealtime insulin, Humalog® 200 could be comfortable option for them. Clinical studies done on Humalog® 200 have established equivalent efficacy & safety versus conventional 100-unit insulin but with half the volume which is a preferred need for patients.
Humalog® 200 comes in an easy to use – KwikPen® that holds twice as many insulin units and require fewer pen changes every month, thus it offers cost-effectiveness to the patients also. This pen is easier to use and administer the injection. Humalog® 200 KwikPen® is suitable for the patients searching for convenient and comfortable mealtime intensification option.
“Diabetes is a big burden on the healthcare system in Bangladesh. More than 13 million people live with diabetes in the country and their treatments are individualized. The launch of Humalog® 200 will open newer avenues in diabetes management and provide health care professionals a better way to manage diabetes. Humalog® 200 will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals Ltd., a leading life science organization that believes in innovation, patient benefit and compliance,” said Halimuzzaman, DMD & CEO, Healthcare Pharmaceuticals Ltd.
Lilly and Healthcare Pharmaceuticals Limited entered into an Agreement for distribution and promotion of Lilly products in Bangladesh. Humalog U200 KwikPen® is a valuable addition to the Lilly Diabetes portfolio in the country given the increasing burden of diabetes in Bangladesh.
“Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. Humalog® 200 is a new, concentrated rapid acting analogue insulin, that has been designed keeping patients’ needs and convenience in mind,” said Prof. A K Azad Khan, President, BADAS.
Humalog® 200 is a prescription drug that should be taken only on advice from registered physicians who deals the diabetic patients. When prescribed, it should be used as an adjunct to diet, exercise and metformin (if not contraindicated).